{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:22Z","timestamp":1789609102065,"version":"build-2803163510"},"reference-count":9,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/100013560","name":"GBS\/CIDP Foundation International","doi-asserted-by":"publisher","award":["Benson Fellowship personal grant to EPG"],"award-info":[{"award-number":["Benson Fellowship personal grant to EPG"]}],"id":[{"id":"10.13039\/100013560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Intravenous immunoglobulin (IVIG) and rituximab are considered the first-line and second-line treatments for Chronic Ataxic Neuropathy and Ophthalmoplegia with IgM-paraprotein, cold Agglutinins, and anti-Disialosyl antibodies (CANOMAD), with an overall clinical response around 50%. New anti-CD38 daratumumab, targeting long-lived plasma cells, has been reported as a promising therapy for treatment-refractory antibody-mediated disorders. We report the first case of a severe refractory CANOMAD, successfully treated with daratumumab.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A patient in their 70s with severe relapsing CANOMAD, refractory to IVIG, steroids, rituximab and ibrutinib developed severe tetraparesis and respiratory failure. Plasma exchange (PE) improved motor and ventilatory function; however, after 6 weeks, patient remained PE dependent. Intravenous daratumumab was initiated at 16\u2009mg\/kg weekly for 3 weeks, every 2 weeks for the second and third month, and monthly afterwards.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>After 3 weeks of starting daratumumab, PE was discontinued and, since then, the patient evolved to complete recovery. Antidisialosyl antibody titres decreased after PE and remained stable during daratumumab. Serum neurofilament light-chain levels were elevated in the exacerbation phase and normalised after daratumumab. The patient remains in clinical remission under monthly daratumumab, 12 months after initiation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The first patient with aggressive treatment-refractory CANOMAD treated with daratumumab provides proof-of-principle evidence that daratumumab may be an effective treatment in IgM-related neuropathies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/jnnp-2023-332443","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T18:20:11Z","timestamp":1707589211000},"page":"609-611","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD"],"prefix":"10.1136","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-4305","authenticated-orcid":false,"given":"Elba","family":"Pascual-Go\u00f1i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Tejada-Illa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1553-2224","authenticated-orcid":false,"given":"Lorena","family":"Mart\u00edn-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-8504","authenticated-orcid":false,"given":"Marta","family":"Caballero-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"Lleix\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"L\u00f3pez-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Esquirol","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Mariscal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"\u00c1lvaro Gargallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8317-7068","authenticated-orcid":false,"given":"Eugenia","family":"Mart\u00ednez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Cocho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"2024071311250959000_95.7.609.1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.10.1968"},{"key":"2024071311250959000_95.7.609.2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24192"},{"key":"2024071311250959000_95.7.609.3","doi-asserted-by":"crossref","first-page":"120279","DOI":"10.1016\/j.jns.2022.120279","article-title":"Are Miller Fisher syndrome and CANDA due to a paranodopathy?","volume":"438","author":"Vallat","year":"2022","journal-title":"J Neurol Sci"},{"key":"2024071311250959000_95.7.609.4","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell\u2013targeted therapies","volume":"136","author":"Le Cann","year":"2020","journal-title":"Blood"},{"key":"2024071311250959000_95.7.609.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"2024071311250959000_95.7.609.6","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/ene.15266","article-title":"Daratumumab for treatment-refractory antibody-mediated diseases in neurology","volume":"29","author":"Scheibe","year":"2022","journal-title":"Eur J Neurol"},{"key":"2024071311250959000_95.7.609.7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2023325"},{"key":"2024071311250959000_95.7.609.8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/mus.23897","article-title":"Canomad: report of a case with a 40-year history and autopsy. is this a sensory ganglionopathy with neuromuscular junction blockade","volume":"48","author":"McKelvie","year":"2013","journal-title":"Muscle Nerve"},{"key":"2024071311250959000_95.7.609.9","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617746640"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-332443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:25:27Z","timestamp":1721067927000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-332443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/jnnp-2023-332443"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-332443","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]}}}